A recipient showing signs and symptoms of thromboembolic abnormalities should be re-assessed before treatment of Depofemme is continued. Recipient suffering from acute visual defects, proptosis, diplopia or migraine, eye tissue should be examined carefully to prevent papilloedema or injury in the retinal blood vessels before treatment is continued. The use of progestin during pregnancy must not be continued, use as a diagnostic test for pregnancy is also not recommended.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
